Harbor Capital Advisors Inc. Lowers Holdings in Elanco Animal Health Incorporated $ELAN

Harbor Capital Advisors Inc. cut its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 13.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 772,062 shares of the company’s stock after selling 124,092 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.16% of Elanco Animal Health worth $11,025,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of Elanco Animal Health by 14.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after buying an additional 2,563,740 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Elanco Animal Health by 1.9% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 15,983,391 shares of the company’s stock valued at $167,826,000 after buying an additional 292,655 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Elanco Animal Health during the 1st quarter valued at $115,212,000. Goldman Sachs Group Inc. raised its position in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Finally, Douglas Lane & Associates LLC raised its position in shares of Elanco Animal Health by 5.6% during the 1st quarter. Douglas Lane & Associates LLC now owns 3,895,190 shares of the company’s stock valued at $40,899,000 after buying an additional 205,241 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ELAN shares. Leerink Partnrs upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. Piper Sandler lifted their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, August 11th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 20th. William Blair upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research report on Thursday, June 26th. Finally, Stifel Nicolaus lifted their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, July 2nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.33.

Elanco Animal Health Trading Up 0.5%

NYSE:ELAN opened at $18.63 on Tuesday. The company’s 50-day simple moving average is $16.45 and its 200 day simple moving average is $13.26. The firm has a market capitalization of $9.25 billion, a P/E ratio of 21.66, a PEG ratio of 3.44 and a beta of 1.62. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $19.08. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the prior year, the firm posted $0.30 earnings per share. The business’s revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.